Literature DB >> 14668540

Advances in pharmacogenomic research and development.

Jeanette J McCarthy1.   

Abstract

Technological achievements in the last 5 to 10 yr and their application to sequencing and polymorphism discovery in the human genome have fostered a renewed interest in the genetic basis of drug response. Consequently, the field of pharmacogenetics/pharmacogenomics has been gaining momentum, fueled not only on technology but also on results of empirical studies of the human genome and on genetic epidemiology studies of real drugs in patient populations. This review discusses some of the recent advances in pharmacogenomic research and development over the last few years that include understanding the architecture of the human genome, the creation of population deoxyribonucleic acid (DNA)/data banks, assessment of the clinical validity of genetic markers, and experience with regulatory aspects of pharmacogenomics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668540     DOI: 10.1385/MB:25:3:275

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  27 in total

1.  Pharmacogenomic-guided drug development: regulatory perspective.

Authors:  L J Lesko; J Woodcock
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

2.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

Review 3.  Genetic associations in large versus small studies: an empirical assessment.

Authors:  John P A Ioannidis; Thomas A Trikalinos; Evangelia E Ntzani; Despina G Contopoulos-Ioannidis
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

4.  Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study.

Authors:  Philip W Lavori; Heidi Krause-Steinrauf; Mary Brophy; Joel Buxbaum; Jennifer Cockroft; David R Cox; Louis Fiore; Henry T Greely; Harry Greenberg; Edward W Holmes; Lorene M Nelson; Jeremy Sugarman
Journal:  Control Clin Trials       Date:  2002-06

Review 5.  Application of DNA microarrays in pharmacogenomics and toxicogenomics.

Authors:  Khew-Voon Chin; A N Tony Kong
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

6.  Genome II: the next frontier.

Authors:  V Brower
Journal:  Nat Biotechnol       Date:  1998-11       Impact factor: 54.908

7.  5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected.

Authors:  V L Nimgaonkar; X R Zhang; J S Brar; M DeLeo; R Ganguli
Journal:  Psychiatr Genet       Date:  1996       Impact factor: 2.458

8.  Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.

Authors:  A K Malhotra; D Goldman; N Ozaki; A Breier; R Buchanan; D Pickar
Journal:  Am J Psychiatry       Date:  1996-08       Impact factor: 18.112

9.  Commentary: meta-analysis of individual participants' data in genetic epidemiology.

Authors:  John P A Ioannidis; Philip S Rosenberg; James J Goedert; Thomas R O'Brien
Journal:  Am J Epidemiol       Date:  2002-08-01       Impact factor: 4.897

Review 10.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.